AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
One step forward, two steps back for biotech.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
